CATALYST BIOSCIENCES, INC. (CBIO) [Rocket]

Date Filed	Type	Description
04/07/2021	GN	Catalyst Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference
03/04/2021	GN	Catalyst Biosciences Reports Fourth Quarter and Full-Year 2020 Operating & Financial Results and Provides a Corporate Update
02/11/2021	GN	Catalyst Biosciences Announces Partial Exercise and Closing of Over-Allotment Option in Public Offering of Common Stock
02/03/2021	GN	Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress
01/29/2021	GN	Catalyst Biosciences Announces Closing of Public Offering of Common Stock
01/27/2021	GN	Catalyst Biosciences Announces Pricing of Public Offering of Common Stock
01/26/2021	GN	Catalyst Biosciences Announces Proposed Public Offering of Common Stock
01/20/2021	GN	Catalyst Biosciences Announces Poster Presentations at the EAHAD 2021 Virtual Congress
12/07/2020	GN	Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design at the 62nd Annual American Society of Hematology Conference
12/03/2020	GN	Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs
11/24/2020	GN	Catalyst Biosciences to Present at 32nd Annual Piper Sandler Virtual Healthcare Conference
11/05/2020	GN	Catalyst Biosciences Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update
10/14/2020	GN	Catalyst Biosciences Receives US Patent for its Anti-Complement Factor 3 Portfolio of Engineered Proteases
09/25/2020	GN	Catalyst Biosciences to Present at the Stifel Immunology and Inflammation Summit
08/06/2020	GN	Catalyst Biosciences Reports Second Quarter 2020 Operating & Financial Results and Provides a Corporate Update
07/01/2020	GN	Catalyst Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/22/2020	GN	Catalyst Biosciences Announces Closing of Public Offering of Common Stock
06/22/2020	GN	Catalyst Biosciences Appoints Charles Democko, Senior Vice President, Regulatory Affairs
06/19/2020	GN	Catalyst Biosciences Presents Preclinical FIX Gene Therapy Data in an Oral Presentation at the World Federation of Hemophilia Virtual Summit 2020
06/17/2020	GN	Catalyst Biosciences Announces Proposed Public Offering of Common Stock
06/15/2020	GN	Catalyst Biosciences Appoints Clinton Musil as Chief Financial Officer
06/15/2020	GN	Catalyst Biosciences Presents Positive Final Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) at the World Federation of Hemophilia Virtual Summit 2020
06/10/2020	GN	Catalyst Biosciences Completes MarzAA Pharmacokinetic & Pharmacodynamic Study
06/08/2020	GN	Catalyst Biosciences Announces Oral and Poster Presentations at the World Federation of Hemophilia Virtual Summit 2020
04/28/2020	GN	Catalyst Biosciences Receives Patent in the European Union for Its Factor IX Portfolio
04/21/2020	GN	Catalyst Biosciences Completes Phase 2b Trial of Subcutaneous Factor IX Dalcinonacog Alfa (DalcA)
02/24/2020	GN	Catalyst Biosciences to Present at the Cowen Healthcare Conference
02/20/2020	GN	Catalyst Biosciences Reports Fourth Quarter and Full-Year 2019 Operating & Financial Results and Provides a Corporate Update